PHARMAC responds on long-acting insulin analogues.

PHARMAC aims to ensure fair allocation of funding across competing new medicines, and must ensure appropriate targeting of medicines to get best value for money. For this reason, our processes for assessing new pharmaceutical funding applications are necessarily diligent. PHARMAC’s process involves both expert clinical review, negotiation with suppliers, consultation with the health sector, and then decision by PHARMAC’s Board. The process is described in the Attachment to this letter (at the end).